Lupin share jumps 3% on launching anesthesia injection in US


Shares of Lupin Ltd rose 3% on 8 november  after the company announced the launch of Rocuronium Bromide injection, an anesthesia medicine, in the United States. 

The launch came after Lupin’s alliance partner Caplin Steriles received approval from the United States Food and Drug Administration (USFDA), the global pharma major said in a filing to the stock exchanges on Wednesday, November 8.

Rocuronium Bromide Injection in the strength of 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) is the generic version of Zemuron injection of Organon USA Inc.

The drug is used for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequences as well as routine tracheal intubation and to give skeletal muscle relaxation during surgery or mechanical ventilation, the pharma major said in a release.


Lupin share jumps 3% on launching anesthesia injection in US

The injection had estimated annual sales of $54 million in the United States, according to the IQVIA MAT August 2023 data. In October, the drug maker secured tentative approval from USFDA for its Abbreviated New Drug Application (ANDA) for tolvaptan tablets.

In September, Lupin entered into an agreement with Menarini India Pvt Ltd to acquire five legacy brands and the associated trademark rights. The brands belonged to strategic therapy areas of Gastroenterology, Anti-infectives and Urology.

Mumbai-headquartered Lupin develops and commercialises a wide range of branded and generic drugs in over 100 markets in the US, India, South Africa, and across the Asia Pacific, Latin America, Europe, and Middle East regions.

It has 15 manufacturing sites, 7 research centers, and more than 20,000 professionals working across the world.


Lupin shares were trading 2.% higher at ₹1,212 on BSE at 1:02 AM.

 So far this year, Lupin shares have surged more than 65%.

2023-10-13 (4)



also read – lemon tree news 

man industry share news


Visit IPOBRAIN home page for latest IPO update


Leave a Comment